Sue’s husband, Philip, was diagnosed with prostate cancer in 2005 and died on Christmas Day 2009, aged 57. 16 years on, she reflects on the legacy he left behind. It was a complete shock to us both ...

Richard Ware, 56, was diagnosed with stage 4 prostate cancer in 2022. Last December, he was told that it had spread to his brain. Following his diagnosis, Richard found out that he carries the BRCA2 ...

The Centre for In Vivo Modelling is a newly established research centre within the Division of Cancer Biology at the ICR. Our scientists and clinical researchers use state-of-the-art in vivo models to ...

Experts at The Institute of Cancer Research, London, have responded to the draft recommendation from the National Screening Committee (NSC) to implement a targeted prostate cancer screening programme ...

Today, the first men have been invited to join the ambitious £42 million TRANSFORM screening trial, kicking off the biggest prostate cancer screening study in a generation. The trial will test the ...

A new type of blood test can accurately identify different types of breast cancer – meaning patients can be matched to the correct treatment without the need for a biopsy. Researchers have shown that ...

Cancer cases in both younger and older adults are increasing, challenging the idea that a global rise is only occurring in the under 50s, a major new analysis has found. An international study, led by ...

Prostate cancer guidelines should change so that all men from the age of 40 with mutations in either the BRCA1 or BRCA2 gene are offered regular PSA testing to detect early signs of the disease, ...

Up to two in five advanced prostate cancer patients could be treated with a combination of two targeted drugs, according to new research. Findings by a team of scientists at The Institute of Cancer ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

Cutting edge proton beam therapy is no better than intensity-modulated radiotherapy for treating people with head and neck cancer, according to new research. The nationwide TORPEdO trial funded by ...